Výsledky vyhledávání - "Joep Vissers"

RAF1 rearrangements are common in pancreatic acinar cell carcinomas

Publikováno v: Modern Pathology. 33:1811-1821

There is now evidence that gene fusions activating the MAPK pathway are relatively common in pancreatic acinar cell carcinoma with potentially actionable BRAF or RET fusions being found in ~30%. We sought to investigate the incidence of RAF1 fusions

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7ecdf562402d71a58a990dc041be410d
https://doi.org/10.1038/s41379-020-0545-9

Zobrazit plný text záznamu

A PP2A-Integrator complex fine-tunes transcription by opposing CDK9

SUMMARYGene expression is tightly controlled by Cyclin-dependent kinases (CDKs) which regulate the RNA Polymerase II (RNAPII) transcription cycle at discrete checkpoints. RNAPII pausing is a CDK9-controlled rate-limiting process that occurs shortly a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cb7dc1e286f1dcefae476501fb5a0246
https://doi.org/10.1101/2020.07.12.199372

Zobrazit plný text záznamu

Abstract PO021: Developing pre-clinical models of uterine leiomyosarcoma

Autor: Gayanie Ratnayake, Tony Papenfuss, Jocelyn Sietsma Penington, Angela Komiti, Ratana Lim, Joshua Tram, Inger Olesen, Emily O'grady, Cassandra J. Vandenberg, Amandine Carmagnac, Genevieve Dall, Justin Bedo, Briony Milesi, Holly E. Barker, Sean M. Grimmond, Clare L. Scott, Joep Vissers, Kym Pham Stewart

Publikováno v: Clinical Cancer Research. 27:PO021-PO021

Uterine sarcomas make up 1-4% of uterine malignancies. Of these 60% are classified as leiomyosarcoma (uLMS). The 5-year survival rate of uLMS is 35-65.2% for tumours that have not spread beyond the uterus. However, women are often diagnosed at a late

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f5583f61e680406b7d70e25144eb9b23
https://doi.org/10.1158/1557-3265.endomet20-po021

Zobrazit plný text záznamu

Abstract PO037: Identifying effective combinations of targeted therapies, using novel pre-clinical models, to improve treatment options for high-grade serous endometrial cancer

Autor: Amandine Carmagnac, Tony Papenfuss, Holly E. Barker, Emily O'grady, Joep Vissers, Justin Bedo, Kym Pham Stewart, Briony Milesi, Clare L. Scott, Cassandra J. Vandenberg, Gayanie Ratnayake, Angela Komiti, Sean M. Grimmond, Ratana Lim, Matthew Wakefield, Joshua Tram, Jocelyn Sietsma Penington, Genevieve Dall

Publikováno v: Clinical Cancer Research. 27:PO037-PO037

High-grade serous endometrial carcinoma (HGSEC) accounts for just 10% of endometrial cancer (EC) cases but is responsible for at least 40% of all EC-related deaths. It typically arises in post-menopausal women, with 70% of patients presenting with st

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::816953f3a8f97e16ecb382de3d15759a
https://doi.org/10.1158/1557-3265.endomet20-po037

Zobrazit plný text záznamu

Abstract PO026: Building the infrastructure required to research novel therapies for 35% of women with endometrial cancer who have rare subtypes

Autor: Clare L. Scott, Holly E. Barker, Amandine Carmagnac, Matthew Wakefield, Ratana Lim, Anthony T. Papenfuss, Cassandra J. Vandenberg, Sean M. Grimmond, Justin Bedo, Joep Vissers, Gayanie Ratnayake, Joshua Tram, Jocelyn Sietsma Penington, Genevieve Dall

Publikováno v: Clinical Cancer Research. 27:PO026-PO026

Whilst the majority of Endometrial Cancers (ECs) are common Type 1 endometrioid cancers, accounting for 75-80% of cases, with a good prognosis, Type 2 ECs include high-grade, clinically aggressive histologies, with poor response rates to hormonal the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::11d177ebed94ce59fa25f609d41a683b
https://doi.org/10.1158/1557-3265.endomet20-po026

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání